Understanding and mapping the opportunities in the market for technologies targeting mrna translation into proteins to treat diseases
mRNA translation targeting the proteins on ribosomes in diseases is a silently growing market area in drug discovery laced with many risks and failures at each stage. Navigating this space is not an easy task and requires expert consulting, with specialists in this space. We have been developing technologies ourselves, while monitoring the space for competition and are up to date with developments and failures in this space, which could serve as your benchmark and roadmap for success.
About TranslaTale
Translatale Biosystems is a biotechnology company founded in 2022 and headquartered in Bangalore, India. The company focuses on drug discovery by targeting ribosomes and mRNA translation processes. It has developed a platform that integrates experimental techniques and data-driven approaches to screen and identify small molecules capable of modulating mRNA translation. By focusing on these fundamental biological mechanisms, Translatale aims to address unmet medical needs in fields such as oncology, neurodegenerative conditions, and rare diseases.
This technology provides researchers and pharmaceutical partners with tools to evaluate the effects of drugs on protein synthesis, serving as a platform for early-stage drug development. The company works to bridge the gap between preclinical research and clinical applications, utilizing approaches like zebrafish xenografts to create patient avatars for personalized and precision medicine. The company is led by its founders, Gnaneshwar Yadav and Saurabh Mahajan, and has been supported by various incubation programs and grants, including from DBT-BIRAC-BIG and IIMB-NSRCEL, to advance its research and development initiatives.
Inquire about this partnering listing
Available for
Industry applications
delivered to your inbox.